UroGen Pharma Valuation
| URGN Stock | USD 9.51 0.23 2.36% |
At this time, the company appears to be undervalued. UroGen Pharma has a current Real Value of $17.33 per share. The regular price of the company is $9.51. Our model measures the value of UroGen Pharma from inspecting the company fundamentals such as Shares Outstanding of 42.2 M, return on equity of -14.81, and Operating Margin of (0.70) % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting UroGen Pharma's valuation include:
Price Book 15.7286 | Enterprise Value | Enterprise Value Ebitda (2.63) | Price Sales 4.4909 | Enterprise Value Revenue 3.0624 |
Undervalued
Today
Please note that UroGen Pharma's price fluctuation is not too volatile at this time. Calculation of the real value of UroGen Pharma is based on 3 months time horizon. Increasing UroGen Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since UroGen Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of UroGen Stock. However, UroGen Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.51 | Real 17.33 | Target 39.93 | Hype 9.59 | Naive 9.13 |
The intrinsic value of UroGen Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence UroGen Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of UroGen Pharma helps investors to forecast how UroGen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of UroGen Pharma more accurately as focusing exclusively on UroGen Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use UroGen Pharma's intrinsic value based on its ongoing forecasts of UroGen Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against UroGen Pharma's closest peers.
UroGen Pharma Cash |
|
UroGen Valuation Trend
Knowing UroGen Pharma's actual value is paramount for traders when making sound investment determinations. Using both UroGen Pharma's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
UroGen Pharma Total Value Analysis
UroGen Pharma is at this time forecasted to have valuation of 273.66 M with market capitalization of 401.32 M, debt of 100.21 M, and cash on hands of 111.74 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the UroGen Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
273.66 M | 401.32 M | 100.21 M | 111.74 M |
UroGen Pharma Investor Information
About 94.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 239.57. UroGen Pharma recorded a loss per share of 3.02. The entity had not issued any dividends in recent years. Based on the key measurements obtained from UroGen Pharma's financial statements, UroGen Pharma may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.UroGen Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. UroGen Pharma has an asset utilization ratio of 46.39 percent. This suggests that the Company is making $0.46 for each dollar of assets. An increasing asset utilization means that UroGen Pharma is more efficient with each dollar of assets it utilizes for everyday operations.UroGen Pharma Ownership Allocation
UroGen Pharma shows a total of 42.2 Million outstanding shares. The majority of UroGen Pharma outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in UroGen Pharma to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in UroGen Pharma. Please pay attention to any change in the institutional holdings of UroGen Pharma as this could imply that something significant has changed or is about to change at the company. Also note that roughly one million three hundred twenty-nine thousand two hundred eighty-one invesors are currently shorting UroGen Pharma expressing very little confidence in its future performance.UroGen Pharma Profitability Analysis
The company reported the previous year's revenue of 82.71 M. Net Loss for the year was (102.24 M) with profit before overhead, payroll, taxes, and interest of 80.67 M.About UroGen Pharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of UroGen Pharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of UroGen Pharma based exclusively on its fundamental and basic technical indicators. By analyzing UroGen Pharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of UroGen Pharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of UroGen Pharma. We calculate exposure to UroGen Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of UroGen Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 84.4 M | 88.6 M | |
| Pretax Profit Margin | (1.07) | (1.12) | |
| Operating Profit Margin | (0.71) | (0.75) | |
| Net Loss | (1.11) | (1.17) | |
| Gross Profit Margin | 0.80 | 0.56 |
UroGen Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 28.8 M |
UroGen Pharma Current Valuation Indicators
UroGen Pharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final UroGen Pharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as UroGen Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use UroGen Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes UroGen Pharma's worth.When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth 0.209 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.